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Abstract
Ophthalmo-acromelic syndrome (OAS), also known as Waardenburg Anophthalmia syndrome, is defined by the
combination of eye malformations, most commonly bilateral anophthalmia, with post-axial oligosyndactyly. Homozygosity
mapping and subsequent targeted mutation analysis of a locus on 14q24.2 identified homozygous mutations in SMOC1
(SPARC-related modular calcium binding 1) in eight unrelated families. Four of these mutations are nonsense, two frame-shift,
and two missense. The missense mutations are both in the second Thyroglobulin Type-1 (Tg1) domain of the protein. The
orthologous gene in the mouse, Smoc1, shows site- and stage-specific expression during eye, limb, craniofacial, and somite
development. We also report a targeted pre-conditional gene-trap mutation of Smoc1 (Smoc1
tm1a) that reduces mRNA to
,10% of wild-type levels. This gene-trap results in highly penetrant hindlimb post-axial oligosyndactyly in homozygous
mutant animals (Smoc1
tm1a/tm1a). Eye malformations, most commonly coloboma, and cleft palate occur in a significant
proportion of Smoc1
tm1a/tm1a embryos and pups. Thus partial loss of Smoc-1 results in a convincing phenocopy of the
human disease. SMOC-1 is one of the two mammalian paralogs of Drosophila Pentagone, an inhibitor of decapentaplegic.
The orthologous gene in Xenopus laevis, Smoc-1, also functions as a Bone Morphogenic Protein (BMP) antagonist in early
embryogenesis. Loss of BMP antagonism during mammalian development provides a plausible explanation for both the
limb and eye phenotype in humans and mice.
Citation: Rainger J, van Beusekom E, Ramsay JK, McKie L, Al-Gazali L, et al. (2011) Loss of the BMP Antagonist, SMOC-1, Causes Ophthalmo-Acromelic
(Waardenburg Anophthalmia) Syndrome in Humans and Mice. PLoS Genet 7(7): e1002114. doi:10.1371/journal.pgen.1002114
Editor: Andrew O. M. Wilkie, University of Oxford, United Kingdom
Received December 29, 2010; Accepted April 15, 2011; Published July 7, 2011
Copyright:  2011 Rainger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for this project was provided as an intramural program grant from the Medical Research Council (UK). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: david.fitzpatrick@hgu.mrc.ac.uk (DRF); H.vanBokhoven@antrg.umcn.nl (HvB)
Introduction
Congenital absence of an eye (here termed anophthalmia) is a
rare malformation in humans with a live birth prevalence of less
than 1 in 10,000 [1]. Identifiable single gene disorders account for
,25% of bilateral anophthalmia. The known genetic causes
include compound heterozygous mutations in PAX6, de novo
heterozygous loss-of-function mutations in SOX2 [2–4], inherited
or de novo heterozygous loss-of-function mutations in OTX2 [5,6],
homozygous loss-of-function mutations in STRA6 [7] and possibly
inherited, heterozygous loss-of-function mutations in BMP4 [8]. In
most cases of anophthalmia no eye is visible on clinical
PLoS Genetics | www.plosgenetics.org 1 July 2011 | Volume 7 | Issue 7 | e1002114examination but optic nerves, chiasm and optic tracts remnants
are visible on magnetic resonance imaging. Absence of the eye
with ipsilateral absence of optic nerves, chiasm and optic tracts is
termed true anophthalmia and is taken to suggest very early failure
of ocular development.
Ophthalmo–acromelic syndrome (OAS), also known as Waar-
denburg anophthalmia syndrome, is one of the most frequently
reported causes of true anophthalmia, which occurs in association
with a distinctive pattern of distal limb anomalies (Figure 1a–1c).
OAS is an autosomal recessive disorder (MIM #206920) first
reported 50 years ago by Waardenburg in two unrelated families
[9]. This original report illustrated the phenotypic spectrum
associated with this disorder. The first family was a sibship of nine
and consisted of two sisters with unilateral anophthalmia, one of
whom had coloboma in her contralateral eye. Both had bilateral
synostosis of the 4th and 5th metacarpals and bilateral postaxial
four-toe oligodactyly with soft tissue syndactyly. A brother had
similar limb involvement but with normal eyes and the other
siblings were reported as normal. In the second family, the
proband was a girl with significant learning disability, bilateral
anophthalmia, short fingers bilaterally and postaxial oligodactyly
with four toes on both feet. Her younger sister was normal. 32
further cases of OAS in 23 different families have been reported
[10–29]. Of the reported definite cases; 32/35 (91.4%) had
anophthalmia (4:28 for unilateral:bilateral), 29 (82.9%) had lower
limb postaxial oligodactyly, 20 (57.1%) had fusion of metacarpals
4–5 and 13 (37.1%) had learning disability. Other recurrent
features included orofacial clefts (4/35) and perinatal or early
postnatal death (10/35) in the 25 families. At the point of
submission of this paper, very little was known of the molecular
basis of OAS. A locus on 10p11.23 with a reported LOD score .3
had been suggested on the basis of linkage analysis in three
unrelated families. However, no pathogenic mutations could be
identified in any of the genes in the linkage interval [17].
Bone morphogenetic proteins (BMPs) account for 10 of the 33
members of the transforming growth factor beta (TGFb)
superfamily of peptide growth factors in humans and are encoded
by the genes BMP2-7, BMP8A, BMP8B, BMP10 and BMP15
(BMP1 does not encode a growth factor but a tolloid-like
protease[30]). BMPs are secreted into the extracellular space
where they bind to BMP type I serine-threonine kinase cell surface
receptors encoded by BMPR1A and BMPR1B. The presence of
BMP type I receptors appears sufficient for BMP binding, but a
BMP type II receptor (encoded by BMPR2, ACVR2A and ACVR2B)
is required for phosphorylation of the BMP type I receptors,
endocytosis and activation of the signal transduction cascade [31].
The intracellular domain of the activated BMP type I receptors in
turn phosphorylates a Ser-Ser-X-Ser (SSXS) motif at the C-
terminal end of one of three homologous protein products of the
human genes SMAD1, SMAD5 and SMAD9. Phosphorylated
SMAD1/5/9 (pSMAD1/5/9 known as regulatory- or R-SMADs)
then bind to the co-SMAD encoded by SMAD4. The co-SMAD/
R-SMAD complex then translocates to the nucleus where it
functions as a transcription factor mediating the activation of
target genes [32]. It has recently become clear that BMP signaling
can also directly induce the activation of the MAPK pathway [33].
The formation of BMP signaling gradients is used extensively
throughout vertebrate embryonic development. The formation
and maintenance of stable developmental gradients appears to
require multiple mechanisms to balance agonistic and antagonist
effects on BMP signaling. The complexity of the system is
demonstrated by the molecular basis of dorsal and ventral
signaling centres in the gastrula of Xenopus laevis embryos [34].
The dorsal signaling centre (DSC; Spemann’s organizer) has the
general effect of antagonizing the Bmp gradient from the ventral
signaling centre. The DSC secretes noggin and chordin, which
(together with twisted-gastrulation [35]) bind to bmp in the
extracellular space and prevents binding to the bmp type I
receptor. The ventral signaling centre (VSC) secretes bmp4 and
bmp7 but also bmper (bmp-binding endothelial regulator) [36]
and sizzled, which inhibits tolloid-like 1, a zinc metalloproteinase
that efficiently cleaves chordin [37]. The VSC also produces
bambi (bmp and activin membrane-bound inhibitor), a bmp
receptor that lacks the catalytic intracellular domain and thus acts
dominant-negatively to inhibit bmp signaling [38].
SMOC-1 is encoded by the human gene SMOC1 (SPARC related
modular calcium binding 1) and was initially characterised as a
basement membrane protein with significant homology to BM-40
(also known as SPARC and osteonectin) [39]. The domain
structure of the SMOC-1 peptide and the close homolog SMOC-2
[40], is evolutionarily conserved [41] and consists from N- to C-
terminus of a follistatin-like domain, two thyroglobulin type I (Tg1)
domains and an EF-hand calcium-binding domain. The ortholog
of SMOC-1 in Xenopus laevis, XSMOC-1, has been shown to
function as a BMP antagonist. Uniquely among the known peptide
BMP antagonists, SMOC-1 was able to antagonize BMP activity
in the presence of a constitutively active BMP receptor. The
molecular basis of this antagonism is not yet clear but may
function by stimulating MAPK-mediated phosphorylation of the
linker (i.e. non-SSXS) region of the R-SMAD proteins [42].
We report the identification of a locus for OAS on 14q24.2 with
subsequent identification of homozygous, predicted loss-of-func-
tion mutations in the SMOC1 gene in eight out of fourteen
unrelated families with OAS. Whole mount in situ hybridisation
(WISH) combined with optical projection tomography (OPT)
shows site- and stage-specific developmental expression of the
orthologous mouse gene, Smoc1, in embryonic limb bud and
craniofacial structures. The phenotype associated with homozy-
gosity for a targeted ‘‘pre-conditional’’ gene-trap mouse mutation
of Smoc1 also shows significant overlap with the human disease.
SMOC-1 and SMOC-2 appear to be the two vertebrate paralogs
of the Drosophila protein Pentagone that has recently been shown to
function as an antagonist of Decapentaplegic (Dpp) signaling in vivo
Author Summary
Ophthalmo-acromelic syndrome (OAS) is a rare congenital
genetic disorder involving complete absence of the eyes
and limb malformations, with missing or fused bones in
the feet and hands. In this paper we report the
identification of genetic changes to both copies of the
SMOC1 gene as the cause of most cases of OAS. We have
identified eight different mutations in this gene in
unrelated individuals, and six of these mutations are
predicted to completely abolish SMOC-1 function. We
have also genetically disrupted the mouse Smoc1 gene to
produce only 10% of normal levels. These animals, called
Smoc1
tm1a/tm1a mice, have similar hindlimb malformations
to those seen in the limbs of human OAS patients,
resulting in missing toes in some mice and fusion of toes in
others. Smoc1
tm1a/tm1a embryos and pups also have eye
malformations but these are milder than those seen in
human cases, perhaps because, unlike the human cases,
the mice still have some residual function of the gene. We
suggest that the normal function of SMOC-1 may be to
regulate an important class of growth factors, called Bone
Morphogenetic Proteins (BMPs), which are essential for
normal embryonic development.
SMOC1 Mutations Cause Ophthalmo-Acromelic Syndrome
PLoS Genetics | www.plosgenetics.org 2 July 2011 | Volume 7 | Issue 7 | e1002114[33]. We discuss the potential role for SMOC-1 in modulating
BMP signaling during eye and limb development.
Results
Mapping and Mutation Analysis
A locus for OAS at 14q24.2 was identified using autozygosity
mapping with 10K SNP chip data from multiple, apparently
unrelated consanguineous pedigrees. Affected individuals from
eight of the fourteen families showed tracks of .20 homozygous
SNPs in a row at this locus (Dataset S1). This locus was confirmed
with multipoint linkage analysis using data from three of these
families giving a combined LOD score of 5.3 (Figure 1d). The
critical region was narrowed to ,1 Mb using microsatellite
markers in four families (Figure 1e). To identify the causative
gene, all coding exons for each gene in the critical region were
sequenced (Figure 1f).
Potentially deleterious mutations were identified in only one
gene: SMOC1, and independent homozygous SMOC1 mutations
were found in eight out of fourteen families (Figure 2a, Table 1).
Of these, 6 mutations predicted complete loss of protein function;
4 are nonsense mutations and 2 are single base deletions or
Figure 1. Mapping ophthalmo-acromelic syndrome. Clinical photographs (a,b) and radiographs (c) of patient R14C12 showing bilateral
anophthalmia, in association with bilateral postaxial oligodactyly and cutaneous syndactyly of 2nd &3 rd toes. (d) Multipoint linkage analysis using 10K
SNPchip data from families 1–3 showing a significant LOD score of Z=5.3 at 14q22.3–24.2, a region also identified by autozygosity mapping (see
Table 1). (e) Microsatellite marker analysis for affected individuals in Families 1–3 and Family 9 showing region of homozygosity, but no common
haplotype. (f) The microsatellite data refined the OAS candidate interval to Chr14:69.89–71.26 Mb which is shown diagrammatically with the 22
annotated genes that were sequenced in this study (UCSC assembly GRCh37).
doi:10.1371/journal.pgen.1002114.g001
SMOC1 Mutations Cause Ophthalmo-Acromelic Syndrome
PLoS Genetics | www.plosgenetics.org 3 July 2011 | Volume 7 | Issue 7 | e1002114insertions resulting in a frameshift. Two different missense changes
were identified, both are in the C-terminal region of the second
thyroglobulin type I domain of SMOC-1 (Figure 2b). No
mutations were identified in sequence analysis of the SMOC1
coding region in 190 healthy blood donors.
No mutations in SMOC1 could be identified in 6 of the 14
families. There were no obvious phenotypic differences between
the cases with and without SMOC1 mutations; all have classical
OAS. SNP and microsatellite data on two of the six families
without detectable mutations showed large regions of homozy-
gosity across the 14q24 region containing SMOC1. This suggests
that we have missed a mutation within the transcription unit or
that there may be a regulatory mutation impairing SMOC1
transcription. In the four remaining families no plausible locus
could be identified using homozygosity mapping.
Expression Analysis of Smoc1
As a first step to determining the likely developmental role of
SMOC1 we undertook developmental expression analysis of the
orthologous gene Smoc1 in whole mouse embryos. WISH analysis
with an antisense riboprobe specific to Smoc1 and optical
projection tomography (OPT) were used to create a 3D
representation of both the anatomy and colorimetric staining.
We found site- and stage-specific expression of Smoc1 at all stages
examined (Figure 3a–3b; Video S1; Video S2). Staining in the
limb bud was particularly interesting with expression seen first in
Figure 2. Mutation analysis. (a) Family pedigrees and associated SMOC1 mutations identified. The pedigree for Family 1 is representative and
shows segregation of a homozygous SMOC1 mutation (c.911delG; p.Asp305MetfsX59) in affected individuals with both parents (and all unaffected
sibs) being heterozygous carriers. (b) Schematic of the SMOC1 gene (top) and predicted protein (below), illustrating the exon positions for all eight
mutations identified in the OAS families. Coding exons are coloured black and numbered, UTRs are brown, protein domains are labeled with amino
acid residue numbers. Red arrowheads indicate the position of the mutations in the peptide. Red asterisks highlight the missense changes, which are
located in the second thyroglobulin domain thought to be involved in the control of proteolytic degradation (n.t.- Sample not tested).
doi:10.1371/journal.pgen.1002114.g002
SMOC1 Mutations Cause Ophthalmo-Acromelic Syndrome
PLoS Genetics | www.plosgenetics.org 4 July 2011 | Volume 7 | Issue 7 | e1002114T
a
b
l
e
1
.
C
l
i
n
i
c
a
l
f
e
a
t
u
r
e
s
a
n
d
m
u
t
a
t
i
o
n
s
i
n
a
f
f
e
c
t
e
d
i
n
d
i
v
i
d
u
a
l
s
w
i
t
h
O
p
h
t
h
a
l
m
o
-
A
c
r
o
m
e
l
i
c
S
y
n
d
r
o
m
e
.
F
A
M
I
L
Y
1
2
3
4
5
6
7
8
A
f
f
e
c
t
e
d
C
a
s
e
R
1
4
A
9
R
1
4
C
1
2
R
1
5
H
1
1
R
2
3
H
3
1
7
7
1
5
1
8
1
7
7
1
5
1
2
4
2
0
3
8
4
2
0
3
8
6
3
0
4
3
3
P
u
b
l
i
s
h
e
d
U
n
p
u
b
l
i
s
h
e
d
G
a
r
a
v
e
l
l
i
e
t
a
l
.
,
(
2
0
0
6
)
K
h
a
n
&
Z
a
f
a
r
,
(
2
0
0
8
)
S
u
y
u
g
u
l
e
t
a
l
,
(
1
9
9
6
)
(
c
a
s
e
3
)
P
a
l
l
o
t
t
a
&
D
a
l
l
a
p
i
c
c
o
l
a
,
(
1
9
8
4
)
U
n
p
u
b
l
i
s
h
e
d
S
a
y
l
i
e
t
a
l
.
(
1
9
9
5
)
P
a
l
l
o
t
t
a
&
D
a
l
l
a
p
i
c
c
o
l
a
,
(
1
9
8
4
)
A
g
e
a
s
s
e
s
s
e
d
1
3
Y
r
9
Y
r
6
M
o
7
M
o
1
8
Y
r
4
0
Y
r
1
1
Y
r
1
4
Y
r
7
Y
r
1
0
Y
r
S
e
x
(
R
a
t
i
o
)
M
M
M
F
M
M
F
M
M
M
E
t
h
n
i
c
i
t
y
L
e
b
a
n
e
s
e
L
e
b
a
n
e
s
e
G
y
p
s
y
P
a
k
i
s
t
a
n
i
T
u
r
k
i
s
h
C
a
l
a
b
r
i
a
n
P
u
e
r
t
o
R
i
c
a
n
T
u
r
k
i
s
h
S
i
c
i
l
i
a
n
C
o
n
s
a
n
g
u
i
n
i
t
y
+
+
+
+
+
+
2
+
+
O
c
u
l
a
r
d
e
f
e
c
t
N
o
n
e
B
A
B
A
U
A
B
A
B
A
B
A
B
A
B
A
B
A
O
p
t
i
c
n
e
r
v
e
/
t
r
a
c
t
/
c
h
i
a
s
m
p
r
e
s
e
n
t
o
n
s
c
a
n
?
2
U
n
k
n
o
w
n
R
e
m
n
a
n
t
s
o
f
o
p
t
i
c
n
e
r
v
e
U
n
k
n
o
w
n
A
b
s
e
n
t
A
b
s
e
n
t
U
n
k
n
o
w
n
U
n
k
n
o
w
n
U
n
k
n
o
w
n
A
b
s
e
n
t
U
p
p
e
r
l
i
m
b
c
u
t
s
y
n
d
c
u
t
s
y
n
d
,
h
y
p
o
p
l
5
t
h
f
i
n
g
e
r
b
i
l
a
t
4
/
5
m
e
t
a
c
a
r
p
a
l
f
u
s
i
o
n
2
b
i
l
a
t
4
/
5
m
e
t
a
c
a
r
-
p
a
l
f
u
s
i
o
n
,
c
a
m
p
t
o
d
a
c
t
y
l
y
b
i
l
a
t
4
/
5
m
e
t
a
-
c
a
r
p
a
l
f
u
s
i
o
n
c
o
n
t
r
a
c
t
u
r
e
s
o
f
f
i
n
g
e
r
s
s
h
o
r
t
5
t
h
m
e
t
a
c
a
r
p
a
l
s
s
h
o
r
t
5
t
h
m
e
t
a
c
a
r
p
a
l
s
c
l
i
n
o
d
a
c
t
y
l
y
5
t
h
f
i
n
g
e
r
s
L
o
w
e
r
L
i
m
b
c
u
t
s
y
n
d
3
–
5
b
i
l
a
t
m
i
s
s
i
n
g
p
o
s
t
a
x
i
a
l
r
a
y
c
u
t
s
y
n
d
2
–
4
r
i
g
h
t
,
2
/
3
l
e
f
t
b
i
l
a
t
m
i
s
s
i
n
g
p
o
s
t
a
x
i
a
l
r
a
y
b
i
l
a
t
m
i
s
s
i
n
g
p
o
s
t
a
x
i
a
l
r
a
y
b
i
l
a
t
m
i
s
s
i
n
g
p
o
s
t
a
x
i
a
l
r
a
y
b
i
l
a
t
m
i
s
s
i
n
g
p
o
s
t
a
x
i
a
l
r
a
y
b
i
l
a
t
m
i
s
s
i
n
g
p
o
s
t
a
x
i
a
l
r
a
y
&
c
u
t
s
y
n
d
2
/
3
R
i
g
h
t
f
u
s
i
o
n
4
/
5
m
e
t
a
t
a
r
s
a
l
&
p
h
a
l
a
n
x
,
c
u
t
s
y
n
d
2
–
5
c
u
t
s
y
n
d
t
o
e
s
2
–
5
c
u
t
s
y
n
d
t
o
e
s
4
/
5
O
t
h
e
r
L
i
m
b
/
S
k
e
l
e
t
a
l
D
e
f
e
c
t
B
o
w
e
d
t
i
b
i
a
C
o
n
t
r
a
c
t
u
r
e
s
o
f
e
l
b
o
w
s
,
C
o
x
a
v
a
l
g
a
T
E
V
,
b
o
w
e
d
t
i
b
i
a
s
C
r
a
n
i
o
f
a
c
i
a
l
2
C
l
e
f
t
p
a
l
a
t
e
2
P
i
e
r
r
e
R
o
b
i
n
S
e
q
u
e
n
c
e
H
i
g
h
l
y
a
r
c
h
e
d
p
a
l
a
t
e
O
t
h
e
r
d
e
f
e
c
t
s
H
o
r
s
e
s
h
o
e
k
i
d
n
e
y
,
h
y
p
o
s
p
a
d
i
a
s
H
o
r
s
e
s
h
o
e
k
i
d
n
e
y
,
m
e
n
t
a
l
r
e
t
a
r
d
a
t
i
o
n
H
o
r
s
e
s
h
o
e
k
i
d
n
e
y
S
e
v
e
r
e
m
e
n
t
a
l
r
e
t
a
r
d
a
t
i
o
n
,
e
p
i
l
e
p
s
y
,
c
r
y
p
t
o
r
c
h
i
d
i
s
m
S
e
v
e
r
e
m
e
n
t
a
l
r
e
t
a
r
d
a
t
i
o
n
H
o
r
s
e
s
h
o
e
k
i
d
n
e
y
S
e
v
e
r
e
m
e
n
t
a
l
r
e
t
a
r
d
a
t
i
o
n
C
o
d
i
n
g
c
h
a
n
g
e
c
.
9
1
1
d
e
l
G
c
.
9
1
1
d
e
l
G
c
.
3
9
5
d
u
p
A
c
.
2
1
2
C
.
T
c
.
1
1
0
9
C
.
T
c
.
2
2
4
C
.
T
c
.
2
7
5
C
.
T
c
.
8
4
8
C
.
A
c
.
8
4
8
C
.
A
c
.
8
3
3
C
.
T
P
r
o
t
e
i
n
c
h
a
n
g
e
p
.
A
s
p
3
0
5
M
e
t
f
s
X
5
p
.
A
s
p
3
0
5
M
e
t
f
s
X
5
p
.
T
y
r
1
3
2
f
s
X
1
p
.
A
r
g
7
1
X
p
.
G
l
n
3
7
0
X
p
.
A
r
g
7
5
X
p
.
G
l
n
9
2
X
p
.
T
h
r
2
8
3
A
s
n
p
.
T
h
r
2
8
3
A
s
n
p
.
A
r
g
2
7
8
C
y
s
E
x
o
n
9
9
4
2
1
1
2
3
8
8
8
M
u
t
a
t
i
o
n
T
y
p
e
F
r
a
m
e
s
h
i
f
t
2
F
r
a
m
e
s
h
i
f
t
2
F
r
a
m
e
s
h
i
f
t
1
N
o
n
s
e
n
s
e
1
N
o
n
s
e
n
s
e
2
N
o
n
s
e
n
s
e
3
N
o
n
s
e
n
s
e
4
M
i
s
s
e
n
s
e
1
M
i
s
s
e
n
s
e
1
M
i
s
s
e
n
s
e
2
I
B
D
1
4
q
2
4
.
2
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
r
=
y
e
a
r
s
;
M
o
=
m
o
n
t
h
s
;
F
=
F
e
m
a
l
e
;
M
=
M
a
l
e
;
U
A
/
B
A
=
U
n
i
l
a
t
e
r
a
l
/
B
i
l
a
t
e
r
a
l
a
n
o
p
h
t
h
a
l
m
i
a
;
I
B
D
=
I
d
e
n
t
i
t
y
b
y
D
e
s
c
e
n
t
;
C
u
t
s
y
n
d
=
c
u
t
a
n
e
o
u
s
s
y
n
d
a
c
t
y
l
y
;
T
E
V
=
t
a
l
i
p
e
s
e
q
u
i
n
o
v
a
r
u
s
;
2
/
3
=
s
e
c
o
n
d
a
n
d
t
h
i
r
d
d
i
g
i
t
s
;
3
–
5
=
t
h
i
r
d
,
f
o
u
r
t
h
a
n
d
f
i
f
t
h
d
i
g
i
t
s
;
2
–
4
=
s
e
c
o
n
d
t
h
i
r
d
a
n
d
f
o
u
r
t
h
d
i
g
i
t
s
;
2
–
5
=
s
e
c
o
n
d
,
t
h
i
r
d
,
f
o
u
r
t
h
a
n
d
f
i
f
t
h
d
i
g
i
t
s
;
4
/
5
=
f
o
u
r
t
h
a
n
d
f
i
f
t
h
d
i
g
i
t
s
;
b
i
l
a
t
=
b
i
l
a
t
e
r
a
l
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
g
e
n
.
1
0
0
2
1
1
4
.
t
0
0
1
SMOC1 Mutations Cause Ophthalmo-Acromelic Syndrome
PLoS Genetics | www.plosgenetics.org 5 July 2011 | Volume 7 | Issue 7 | e1002114the very early limb bud anlage from 9.5 dpc (Figure 3a). At 10.5
dpc the limb expression distinctly localised to both the dorsal and
ventral surfaces of the forelimb, but was predominantly dorsal in
the hindlimb bud (Figure 3b, Figure S1). Strong expression was
seen in the developing pharyngeal arches and the frontonasal
region with low-level expression in the ectoderm overlying the
developing optic vesicle (Figure S1). Using WISH and OPT no
clear expression of Smoc1 was detected in the optic vesicle itself.
There was clear expression in the developing somites at E9.5 and
E10.5 (Figure 3a, 3b). At E9.5 there was also staining in the
hindbrain (Figure 3a) and at E10.5 strong staining in the dorsal
neural tube (Figure 3b).
Targeted Mutation in Mouse Smoc1
In order to determine if the non-redundant developmental role
of SMOC1 is evolutionarily conserved we obtained mice with a
targeted Pre-Conditional mutation in Smoc1 containing a LacZ
reporter allele created as part of the EUCOMM project [43].
The integrated location and the details of the targeting construct
are shown in Figure S1d. The Smoc1
tm1a/tm1a mice have ,10% of
wild-type levels of Smoc1 mRNA during development (Figure
S1f), presumably as a result of splicing across the gene-trap
insertion.
Using the LacZ reporter in targeted animals, we were able to
further assess the developmental expression of Smoc1 (Figure 3c,
3d, and 3g). Spatial and temporal expression data were similar
between Smoc1
+/tm1a and Smoc1
tm1a/tm1a genotypes, but with less
intense staining in Smoc1
+/tm1a mice (data not shown). The X-gal
staining at E10.5 of both whole mount embryos and cryosections
was consistent with the wild type OPT data. Cryosections through
the maxilliary-mandibular hinge region of the 1
st pharyngeal
(branchial) arch at E10.5 showed striking regional specificity of
gene activation (Figure 3g). The expression was present within the
mesenchyme or neural crest of both components of the first arch
but is most intense in the sub-epithelial mesenchyme within the
hinge region. Sharp boundaries of expression are evident in the
subepithelial mesenchyme (Figure 3g). The only major difference
between the riboprobe WISH analysis and the X-gal staining was
the strong expression identified within the developing eye seen in
the latter but not the former (Figure 3c). This staining was
particularly strong at E10.5 within the ventral aspect of the
developing optic nerve (Figure 3d).
Further phenotypic analysis of mutant animals showed that
limb malformations were present in a high proportion of embryos
and pups (Table 2). Oligodactyly (+/2 fibular agenesis) or
osseous syndactyly of both hindlimbs was present in 11/12 of
Smoc1
tm1a/tm1a animals (Figure 3j–3k and Figure S1). Smoc1
tm1a/tm1a
embryos and neonates were also smaller than littermates but did
not appear to have any other major malformations (Figure S2).
To date all Smoc1
tm1a/tm1a animals allowed to litter have died at or
soon after birth. A proportion of this perinatal lethality is likely be
related to the presence of cleft palate in a significant proportion (4
of 12) of the Smoc1
tm1a/tm1a animals (Figure 3i). However it is not
clear what accounts for the mortality in the non-cleft cases.
Interestingly, unexplained perinatal lethality is reported in human
OAS families (see Introduction).
Eye malformations were apparent in a significant proportion of
the homozygous embryos or pups. We observed iris and retinal
coloboma in 55.6% of the homozygous animals that could be
accurately phenotyped (Figure 3f). Extension of the retinal
pigmented epithelium (RPE) into the optic nerve (figure 3e), and
a reduction in optic nerve diameters (Figure S2) was also observed
in these mice.
Discussion
We report compelling evidence that loss-of-function mutations
in SMOC1 cause a significant subset of OAS cases. No non-
synonymous changes were found in any region of the SMOC1
coding region in the 190 control individuals that were fully
sequenced but we identified eight mutations within OAS families
that are all different and homozygous. Six of these mutations (four
nonsense and two frame-shift) are very likely to result in severe or
complete abrogation of protein function. The two missense
mutations (p.Arg278Cys & p.Thr283Asn) we have identified are
both located in the second thyroglobulin type-1 domain (Tg1) of
SMOC-1. Tg1 domains are cysteine-rich motifs that were first
identified in the C-terminal region of thyroglobulin which appear
to function as peptidase inhibitors, specifically inhibitors of
cysteine cathepsins [44,45]. Neither Arg278 or Thr283 show
identity at the equivalent residue within the first Tg1 in human
SMOC-1. However, both residues show complete conservation
with the second Tg1 in both mouse and Xenopus tropicalis Smoc-1
and Thr283 is conserved in the second Tg1 in Drosophila
Pentagone (see Figure S3). The mutation of Arg278 to Cys may
disrupt the highly conserved pattern of disulphide bonding within
the second Tg1 [41]. Given that there is no obvious difference
between the missense mutation cases and those with null
mutations, it is reasonable to speculate that inhibition of a
developmentally expressed peptidase, possibly a cysteine cathep-
sin, may be the non-redundant developmental function of SMOC-
1. Interestingly, Cathepsin H has been shown to be involved in
Bmp4 degradation during lung development [46]. It is also
possible that a mutation resulting in constitutive activation of the
target peptidase could phenocopy SMOC1 mutations.
The expression analysis and targeted partial gene inactivation in
mouse embryos strongly supports the critical and non-redundant
developmental role of SMOC-1 suggested by the human genetic
analysis and that this role is conserved across evolutionary time.
The hindlimb phenotype in Smoc1
tm1a/tm1a homozygous mice was
very similar to the lower limb phenotype in human OAS cases.
The combination of osseous syndactyly and oligodactyly suggest
that the mechanisms controlling digit number within the limb bud
are significantly impaired. The control of digit number is critically
dependent on correct dosage of sonic hedghog (Shh) [47,48]
and BMP4 & BMP7 signaling proteins [49,50]. A significant
proportion of the Smoc1
tm1a/tm1a homozygous mice have cleft
palate, a feature common to human OAS and consistent with the
high level of expression of Smoc1 that was detected in the
developing first pharyngeal arch. The eye malformations seen in
the mouse were less severe than those seen in human OAS cases,
being predominantly iris and retinal coloboma. This may relate to
the difference in mutation type between the mouse and human
cases: most human mutations are apparently null, whereas the
mouse line had 10% of normal Smoc1 transcript levels present,
most likely due to splicing across the gene trap. This level of Smoc-
1 function could partially rescue the ocular phenotype in the mice.
Analysis of the phenotype associated with a null allele in mice that
we are currently making will answer this question. We will also
screen a cohort of human patients to determine if hypomorphic
mutations in SMOC1 may cause coloboma.
The formation of precise gradients of diffusible ligands is
required during embryogenesis both for patterning - the formation
of complex tissue structures from apparently homogenous
populations of multipotent cells - and to control growth to achieve
correct final organ size with appropriate symmetry of paired
structures. BMPs represent an important class of diffusible ligands
with roles in both patterning and control of organ size [51,52].
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Smoc1 expression at embryonic day (E) 9.5 (green represents Smoc1 expression); Smoc1 is expressed in the pharyngeal (branchial) arches (BA), the
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function of BMP gradients derived from studies of Drosophila
Decapentaplegic (Dpp) [53]. BMPs are considered to be the
mammalian paralogs of Dpp. SMOC-1 and its close homolog
SMOC-2 appear to be the mammalian paralogs of Drosophila
Pentagone (Pent) [54]. Pent functions as an in vivo antagonist of
Dpp by preventing receptor endocytosis close to its source thus
allowing gradients to form over wider distances within the wing
imaginal discs. Lack of Pent results in a very steep and narrow
gradient of Dpp signaling, which in turn causes a relative
deficiency of Dpp further from the source. In Drosophila the
control of cell proliferation within the wing imaginal disc is
dependent on Dpp signaling [55]. In the chick it has been shown
that the level of cell proliferation within the limb bud must be
precisely specified to in order to result in sufficient antero-posterior
expansion to form the correct digit number [48]. If a similar
mechanism exists in vertebrates then it may be that SMOC1/Smoc1
mutations could cause oligodactyly by altering the BMP gradient
within the limb bud and thus alter anteroposterior expansion.
Although the molecular basis of the developmental pathology
associated with OAS remains to be elucidated, support for
SMOC-1 mediated BMP antagonism as a component is provided
by human and mouse genetic data that indicate the importance of
BMP signalling in both limb [56,57] and eye [8,58,59]
development. Interestingly, heterozygous BMP4 mutations have
been associated with microphthalmia, microcornea, coloboma,
retinal dystrophy, and tilted optic disc [8]. In addition, BMP4
mutations are also associated with digital anomalies (polydactyly)
and cleft lip/palate [60]. The partial overlap between the OAS
phenotype and the phenotypes associated with BMP4 disruptions
may reflect a functional relationship between SMOC-1 and
BMP4.
Following submission of this paper two other groups have
identified SMOC1 mutations as a cause of OAS [10,61]. One
group studied five affected individuals from four unrelated OAS
families [61]. They identified the locus on 14q24 and then found
SMOC1 mutations in three out of four of the families. Interestingly
these were the same families in whom linkage to 10p11.23 had
been previously reported by the same group [17]. The SMOC1
mutations were all homozygous and plausibly loss of function (one
nonsense and two 59 splice site mutations). This group also
reported the phenotype in homozygous mice with Sleeping beauty
transposon-induced gene trap mutations of Smoc1. The expression
analysis and limb phenotype of the mice are very similar to that
reported here. Their homozygous mice also showed unexplained
uniform early lethality. Interestingly their mice had small eyes but
they do not report coloboma. The optic nerves were shown to be
significantly narrower than non-homozygous animals and they
also showed extension of the RPE into the optic nerve. The second
paper reports linkage to 14q24 and identification of a 59 splice site
mutation in SMOC1 in a single multiplex family with OAS [10].
This group also reports developmental expression analysis of the
orthologous gene, smoc1, in zebrafish embryos. Expression was
evident in the brain, choroid fissure and pharyngeal arches.
‘‘Knock-down’’ experiments using a morpholino targeted to smoc1
resulted in microphthalmia and brain abnormalities in the injected
embryos. Taken together these papers strongly support loss of
SMOC-1 function as the major cause of OAS and that this protein
has a conserved non-redundant function during ocular and limb
development.
Finally, in six families with typical OAS we could not identify
SMOC1 mutations, including the original family described by
Waardenburg in 1935 [9]. In two of these six families, affected
individuals show homozygosity over the region of 14q24.2
suggesting that we have significant limitations in our current
SMOC1 mutation analysis strategy. However, four families showed
no apparent autozygosity around SMOC1, suggesting the likely
existence of other OAS loci. Identifying causative genes at other
loci is likely to help elucidate the embryopathology and is an active
area of our future work.
Materials and Methods
Patient Recruitment and Ethics Approval
All patient related work was carried out with full written consent
of the families. Details of the mutation positive cases are provided
in Table 1. The informed consent process was reviewed and
approved following consideration by national ethical committee
systems in the UK and the Netherlands. Several of the cases have
been previously published. [16,19,22,25,26]
Mapping and Linkage Analysis
Patient, parental and unaffected sib genomic DNA samples
were run on Affymetrix GeneChip Human Mapping 10K Arrays
(Xba131) and autozygosity mapping was performed using
rostral neural tube (NT), in the anlage of the forelimbs (FL), the fronto-nasal region (FN), and in the somites (S). (b) At E10.5, expression is maintained
in the branchial arches, somites and in the frontal nasal processes, as well as extending caudally in the neural tube. (c) In E10.5 Smoc1
tm1a/tm1a
embryos, b-galactosidase activity was observed in tissues consistent with the OPT analysis of WT Smoc1 expression: in the dorsal hindlimbs; in the
medial regions of dorsal and ventral forelimbs, the branchial arches, in the frontonasal processes, and in the somites. In addition, strong signal was
observed in the eye region (scale bar=500 mm). (d) X-gal stained sagittal sections of a representative E10.5 Smoc1
tm1a/tm1a embryo in the developing
eye showing that expression was restricted to ventral regions of the presumptive optic stalk (POS). (e) Examination of optic nerve morphology
identified an extension of the RPE into the dorsal optic nerve in mutant animals compared to control. (f) Photographs of Smoc1
tm1a/tm1a eye showing
an optic fissure closure defect (arrowhead) consistent with coloboma (scale bars=100 mm). (g) Expression in the 1
st branchial arch mesenchyme was
distributed in proximal regions and absent from distal areas, with positive signal also seen in the epithelial cells at the hinge region between
maxilliary (MX) and mandibular (MD) components (arrowheads) (scale bar=100 mm). (h,i) Pictomicrographs of sections through E14.5 heads showing
a failure in palatal shelf (PS) fusion in the developing palate in the Smoc1
tm1a/tm1a embryo (i) compared to the fully fused WT littermate (h). (j,k)
Surface rendered visualization of OPT reconstructions of hindlimbs at E14.5. (j) WT embryo with normal arrangement of 5 digits in the hindlimb
whereas the Smoc1
tm1a/tm1a littermate (k) had hindlimb oligodactyly affecting the axial digits, with only 4 digits present. (l) Skeletal preparation of P0
Smoc1
tm1a/tm1a hindlimb with osseous fusion of the phalanges of digits 3–4 (red arrow).
doi:10.1371/journal.pgen.1002114.g003
Table 2. Phenotypes identified in Smoc1-targeted mice.
Genotype Smoc1
tm1a/tm1a Smoc1
+/tm1a Smoc1
+/+
Total analysed 12 (26%) 21 (45.7%) 13 (28.3%)
Eye phenotype 5 (n=9*; 55.6%) 0 0
Hind limb phenotype 11 (91.7%) 0 0
Cleft palate 4 (33.3%) 0 0
Missing fibula 6 (50%) 0 0
*3 confirmed Smoc1
tm1a/tm1a animals were embedded in paraffin before eye
phenotype was established.
doi:10.1371/journal.pgen.1002114.t002
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ALOHOMORA and Allegro (V1.2c). Gene data in the candidate
interval were retrieved from the Ensembl Human genome
(GRCh37 assembly; http://www.ensembl.org/Homo_sapiens/
index.html). Microsatellites containing tri- or tetranucleotide
repeats (Table 3) were identified from the UCSC browser (http://
genome.ucsc.edu/index.html) and PCR primers were designed
using Primer3 (http://frodo.wi.mit.edu/primer3/). FAM fluores-
cent labels were placed at the 59-end of the forward primer. All
microsatellites were tested for informativeness for each family.
PCR and Sequence Analysis
Genomic DNA samples were Whole Genome Amplified (WGA)
using the Illustra GenomiPhi V2 DNA Amplification Kit (GE
Healthcare) according to the manufacturer’s guidelines. For PCR,
50 ng WGA template DNA was amplified with 0.2 mM primers
and 2x Custom Reddymix (Thermo Scientific) in H2Ot o2 5ml.
Cycle conditions: 95uC63 minutes; and 356cycles of 95uC61
minute, 56uC645 seconds, and 72uC61 minute; followed by a
single step of 72uC610 minutes. All mutations were confirmed by
resequencing using non-WGA genomic DNA with identical
reaction conditions. Sequencing was performed using Applied
Biosystems 3130/3170 Genetic Analysers. Genbank sequences
were downloaded from NCBI build 37.2 and mutation analysis
was performed with Mutation Surveyor Software (SoftGenetics
LLC, PA, USA) or Sequencher 4.8 (GeneCodes Corp. MI, USA).
In Situ Hybridisations
To generate a DNA tempate for production of Smoc1 riboprobe,
PCR was performed from mouse genomic DNA targeting the 39
untranslated region (UTR) of the Smoc1 gene using primers with T3
and T7 RNA polymerase sites at the 59 ends of the forward
and reverse primers respectively (underlined) (Smoc1 Forward
59- AATTAACCCTCACTAAAGGCGTGTGTGGTTTGTTT-
CTGG-39; Smoc1 Reverse 59- TAATACGACTCACTATAG-
GTAGACTGCCAAGGGATCTGG-39). Digoxigenin (DIG) la-
belled (Roche) sense and antisense riboprobes were generated by in
vitro transcription using T3 and T7 RNA polymerase respectively.
Whole-mount in situ hybridization to mouse embryos at 9.5 & 10.5
days post-coitum (dpc or E9.5/E10.5) was carried out as previously
described [62]. Briefly embryos were fixed overnight in 4%
paraformaldehyde (PFA) at 4uC, proteinase K (10 mg/ml) (Roche)
treated for 15–35 minutes, depending on the stage then washed
twice in 0.1 M triethanolamine, washed in phosphate-buffered
saline (PBS) -Tween (0.1%) and refixed in 4% PFA/0.2%
glutaraldehyde for 20 minutes. Prehybridisation was performed
for 2 hours and hybridisation for 40 hours at 60uC in hybridisation
buffer containing each DIG labelled probe. Washes were in
26hybridisation buffer for 10 minutes, 3626SSC +0.1% Tween
20 for 20 minutes, 360.26SSC +0.1% Tween 20 for 30 minutes, all
at 60uC. At room temperature the embryos were washed in 1 M
Malic Acid with 2% BMB (Boehringer- Mannheim blocking
reagent) +20% heat-treated lamb serum solution for 2 hours and
then in the same buffer containing a 1/2000 dilution of anti-DIG
antibody coupled to alkaline phosphatase (Roche) overnight at 4uC.
Embryos were washed 365 minutesand 361 hour in MAB. Colour
detection was performed in 2 ml of BM purple precipitating
solution (Roche).
Smoc1 Targeted Mouse
The Smoc1 pre-conditional knockout mouse (EUCOMM Project
48154; strain C57BL/6N-A-Smoc1
tm1a(EUCOMM)WTSI, referred to
as Smoc1
tm1a in this manuscript) was generated by the International
knockout Mouse Consortium (IKMC) under UK Home Office
Project License 60/3785 (IJ Jackson, MRC Human Genetics
Unit).Detailsofthealleleandtargetingstrategycanbefoundat:http://
www.eucomm.org/htgt/report/gene_report?project_id=48154 and
in Figure S1. Genotypes were confirmed using the Smoc1 forward
primer 59-GGTCTGACTCGGTAGGCTTG- 39 (positioned at
mChr12:82,236,250 bp) and Smoc1 reverse primer 59-CCTCT-
CTCCAACCCTTTTCC-39 (positioned at mChr12:82,236,907 bp)
which flank the targeted endogenous exon and produce a wild type
PCR amplicon of 658 bp. Adding the targeting cassette specificprimer
59- TTAGTCCCAACCCCTTCCTC-39 to PCR mixes as multiplex
reactions produced a targeted-allele specific amplicon of 250 bp. Ear-
clip DNA was extracted by incubating in 50 mlo f2 5m MN a O H
0.2 mM EDTA solution at 95oC for 1 hour, then adding 50 mlo f
40 mM Trizma. 1 ml of template was used for PCR reactions with
0.2 mMprimersand2xCustomReddymix(ThermoScientific)inH2O
to 50 ml. Cycle conditions: 95uC63m i n u t e s ;a n d3 1 6cycles of
95uC645 seconds, 56uC640 seconds, and 72uC61 minute; followed
by a single step of 72uC610 minutes. Products were run on 1% TBE
agarose gels. For qRT-PCR, mouse hind limbs at stage 10.5 dpc were
dissected and mRNA extracted using TRIzol(Invitrogen)according to
the manufacturers instructions. Mice were genotyped by PCR using
genomicDNAasdescribedabovewithWTandSmoc1
tm1a/tm1asamples
carried on for testing. Samples were DNaseI treated and then cycled
using Power SYBR Green RNA-to-CT 1-Step Kit (Applied
Biosystems) using an ABI-HT7900 SDS instrument (Applied Biosys-
tems) with the following conditions: 48uC630 minutes, 95uC610
minutes, followed by 40 cycles of 95uC615 seconds and 60uC61
minute. Each 10 ml reaction contained 0.08 mlo fR TE n z y m eM i x ;
5 mlo fR T - P C RM i x ;1mlR N As a m p l ea n d1 . 9 2mls d H 2O, with the
Table 3. Microsatellite repeat marker PCR and primer properties.
Microsatellite (Chr14: bp) Forward primer Reverse primer Approx size (Repeat type)
D14S6790 (67906158–67906384) CTGACAATTTGGGGAAAAGG GGTACTGCTCTGAGGTCTGGA 320 bp (tetra)
D14S6889 (68892553–68892831) TCTGGAGGACTCAGAAGAAGAGA CCCAGGCAACAAGAGTGAA 300 bp (tetra)
D14S6921 (69216842–69217056) CAGCTACTTCCACCGTCTCC ACACTTGGTGCCCTTGAAAC 200 bp (tetra)
D14S6974 (69749225–69749449) CGCCCTTGGAAATGATTTTT GATAGCACCACTGCACTCCA 250 bp (tetra)
D14S258 (70583011–70583186) TCACTGCATCTGGAAGCAC CTAACTAAATGGCGAGCATTGAG 170 bp (di)
D14S6985 (70786661–70786943) CTCCATGAAACACCCAGTCC GGCAGAAAAATCGCTTGAAC 285 bp (tetra)
D14S7023 (71168266–71168625) AGGGGTTAGCGAGAAGGAAG GCAGGTAGAGGATGCCAGAG 330 bp (tri)
D14S7033 (71259290–71260458) TGAGCCCAGGAGTTCAAGAC AGCTCCCAGCATAGTTCCAG 270 bp (tetra)
doi:10.1371/journal.pgen.1002114.t003
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CAGG-39 and reverse 59- TCATCTCCATCGAACACAGG-39
primers or Hprt forward 59- CTGGTGAAAAGGACCTCTCG -39
and reverse 59- CAAG-
GGCATATCCAACAACA-39primers.Eachreactionwasperformed
in triplicate in optical reaction plates (384-well, Applied Biosystems),
andRNAsampleswerealsorunwithoutRTEnzymeMixfornegative
controls with the same reaction conditions.
Histological and Histochemical Analysis
Embryos were fixed in 4% PFA; dehydrated through graded
alcohol series and xylene; and embedded in paraffin. Microtome
sections were cut at 6 mm and rehydrated through ethanol series
and stained with haematoxylin and eosin. For skeletal preparations
the animals were dehydrated in 95% ethanol for 24 hours; followed
by 72 hours in 100% acetone; 3 days in stain solution (1 part 0.3%
alcian blue in 70% ethanol; 1 part 0.1% alazarin red in 95%
ethanol; and 1 part acetic acid, in 17 parts 70% ethanol); followed
by 3 days clearing in 1% KOH; 3 days in 1% KOH/30% glycerol;
and two 24 hour periods in 1% KOH/50% glycerol; in 1% KOH/
70% glycerol and were analysed in 100% glycerol. X-gal (5-bromo-
4-chloro-3-indolyl-b-D- galactopyranoside) staining was performed
as follows: targeted mouse embryos were dissected at 10.5 dpc and
rinsed in PBS, then fixed for 1 hour in 4% PFA at 4oC, rinsed again
inPBSandthen washedfor3x20minutesindetergent wash(2 mM
MgCl2, 0.1% Sodium Deoxycholate, 0.02% NP-40 [Igepal CA
630], in PBS). Detection was performed in b-galactosidase stain
(0.085% NaCl, 5 mM K3 [Fe(CN)6], 5 mM K4 [Fe(CN)6],
200 ml/ml X-gal (Promega), in detergent wash), followed by a brief
final stain fixation in 4% PFA for 30 minutes. For cryosection
analysis, embryos were dissected and fixed as above, then incubated
overnight in 20% sucrose/PBS at 4uC, transferred into OCT
solution and frozen embedded on dry ice. Sections of 25 mm
thickness were cut at 220uC, air dried and rinsed briefly in PBS. X-
gal staining was then performed as described above.
Optical Projection Tomography
For optical projection tomography (OPT) analysis In Situ stained
embryos were mounted in 1% agarose, dehydrated in methanol
and then cleared overnight in BABB solution (1 part Benzyl
Alcohol: 2 parts Benzyl Benzoate). Samples were then imaged
using a Bioptonics OPT Scanner 3001 (Bioptonics, UK) using
brightfield analysis to detect tissue autofluorescence for capture of
anatomical and signal data (wavelengths: excitation at 425 nm,
emission: 475 nm). The resulting data were reconstructed using
Bioptonics proprietary software (Bioptonics, MRC Technology,
Edinburgh, UK), then automatically thresholded to remove
background and finally merged into a single 3D image output
using Bioptonics Viewer software.
Supporting Information
Figure S1 Expression of Smoc1 in the limb buds and eye, and
phenotype in Smoc1
tm1a/tm1a limbs. (a–c) Magnified images and
digital section of the same OPT reconstruction of a wild-type
E10.5 embryo shown in Figure 2 with green staining representing
Smoc1 expression. (a) Smoc1 expression is seen in both the dorsal
and ventral surface of the forelimb buds. (b) In the hindlimb
expression is predominantly dorsal and with small region of
ventral expression. (c) Digital section showing symmetrical low-
level expression of Smoc1 in the surface ectoderm overlying the
optic vesicles (OV). (d) Diagram illustrating the gene targeting for
the EUCOMM pre-conditional Smoc1 knockout mouse at the
genomic level (top) with the relative positions of RT-PCR primers
indicated. Targeting cassette (bottom) is specific for exon 4 of
Smoc1. Positions of genotyping PCR primers are indicated (GT-F
& -R2, blue, are endogenous-gene specific, GT-R1 is cassette-
specific) Note that the targeting cassette has the b-galactosidase
ORF inserted downstream of an EN2 splice acceptor site (EN2
SA) and internal ribosomal entry site (IRES), allowing for reporter
expression in successfully Smoc1-targeted animals (pA is Poly(A)
tail). The cassette also features FRT and Cre-recombinase (loxP)
sequences for future gene manipulation. Ensembl exon identifiers
are given. A table of the phenotypes associated with the targeted
allele is available in Table 2 of the main manuscript. (e) Agarose
gel indicating each allele identified by genotyping PCR primers.
A=phenotypically wild type animal, B=littermate with hindlimb
oligodactyly, Wt=wild type unrelated mouse DNA sample.
Primer pair 1 (GT-F & GT-R2) amplified wild type allele only,
Primer pair 2 (GT-F & GT-R1) amplified the targeted allele only,
multiplex reaction (GT-F & GT-R2 & GT-R1) identified both WT
and mutant alleles and revealed animal B as a Smoc1 homozygote
(Smoc1
tm1a/tm1a) and A as a heterozygote (Smoc1
+/tm1a). Multiplex
reactions were then used as standard for genotyping Smoc1 status in
analysed animals. (f) Quantitative RT-PCR analysis of dissected
hindlimb tissue from E10.5 wild type and homozygote animals
revealed significant reduction of Wt Smoc1 mRNA in mutant
animals (WT, n=2; Smoc1
tm1a/tm1a, n=4). (g) Skeletal preparation
of P0 Smoc1
tm1a/tm1a hindlimb showing absent fibula (arrow) (T-
tibia; F-femur).
(TIF)
Figure S2 Phenotypic analysis and X-gal staining of Smoc1
mutant animals. (a & b) Low power magnification of H&E stained
eyes revealed that mutant eyes were grossly normal but that overall
eye size was reduced. (c & d) Higher magnification analysis
revealed normal organization and retinal cell-layer lamination in
Smoc1
tm1a/tm1a mutant eyes. Abbreviations: c, cornea; ln, lens; r,
retina; gcl, ganglion cell layer; inl, inner nuclear layer; onl, outer
nuclear layer; rpe, retinal pigmented epithelium (Scale bars: a &
b=250 mm; c, d & e=100 mm). (e) Maximum width measure-
ments were taken for optic nerves (on) of Smoc1
tm1a/tm1a mutants
(n=17) and controls (n=11) from paraffin-embedded sections (f)
This plot shows the significantly smaller mean diameter of the
optic nerve in mutants compared to control animals with the error
bars representing the non-overlapping of 95% confidence limits;
125.7 mm (118.2–133.3) and 147.0 mm (139.6–154.5) respectively.
(g,h) Transverse digital sections from OPT scans of E14.5 WT and
Smoc1
tm1a/tm1a embryos showing an apparently normal size and
shape of developing kidneys (arrows). Scale bar=1 mm. (i) Whole
mount X-gal stained Smoc1
tm1a/tm1a embryo at E14.5. This embryo
was dissected to reveal the developing kidneys. No X-gal positive
cells can be seen in the kidneys (LK, left kidney; RK, right kidney)
or bladder (B). Stain is clearly seen in both adrenal glands
(arrowheads) and in tissue adjacent to the developing vertebrae
(V). Scale bar=500 mm. (j) Sagittal cryosection of 25 mm thickness
counterstained with eosin showing strong X-gal staining in the
tissue between the developing vertebral bodies (VB). (k) E14.5
stage left kidney seen in i. No stain positive cells can be seen within
the kidney (KID) but a cluster of positively staining cells are seen
within the adrenal (ADR). Scale bar=100 mm.
(TIF)
Figure S3 Alignment of human SMOC-1 Thyroglobulin type-1
(Tg1) domains with Tg1 domains from mouse Smoc-1, Xenopus
tropicalis Smoc-1 and Drosophila melanogaster Pentagone.
Alignment of the Tg1-1 and Tg1-2 domains from mouse Smoc-
1 and human SMOC-1 with the Tg1-2 domains from Xenopus
tropicalis Smoc-1 and Drosophila melanogaster Pentagone. The
SMOC1 Mutations Cause Ophthalmo-Acromelic Syndrome
PLoS Genetics | www.plosgenetics.org 10 July 2011 | Volume 7 | Issue 7 | e1002114position of identical amino acid residues across all sequences is
given by pink shading. The gray shading indicates the conserva-
tion of the positions in the Tg1-2 affected by the missense
mutations and the nature and position of the mutations is shown in
red text below. Key: Tg1=Thyroglobulin type-1 domain; Tg1-
1=first Tg1 in the peptide; Tg1-2=second Tg1 in the peptide;
hSMOC1=human SMOC1; mSmoc1=mouse Smoc1;
xtSmoc1=Xenopus tropicalis Smoc1; dmPent=Drospophila melanoga-
ster Pentagone protein; Q9h4F8 etc are UniProt accession
numbers.
(DOC)
Video S1 OPT analysis of Smoc1 expression in wild-type E9.5
mouse embryo.
(MPG)
Video S2 OPT analysis of Smoc1 expression in wild-type E10.5
mouse embryo.
(MPG)
Dataset S1 UCSC custom track for the hg18 genome build that
represents the distribution of homozygous regions in the
individuals affected with Ophthalmo-acromelic syndrome in our
study. The homozygous regions are defined as the genomic
coordinates encompassing 20 contiguous homozygous genotypic
calls. The regions surrounding SMOC1 shows the multiple
overlapping homozygous regions in unrelated families and
provides a graphical representation of the linkage of OAS to this
region of chromosome 14.
(TXT)
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